Geoffrey W Krampitz, Jeffrey A Norton, George A Poultsides, Brendan C Visser, Lixian Sun, Robert T Jensen
{"title":"Lymph nodes and survival in pancreatic neuroendocrine tumors.","authors":"Geoffrey W Krampitz, Jeffrey A Norton, George A Poultsides, Brendan C Visser, Lixian Sun, Robert T Jensen","doi":"10.1001/archsurg.2012.1261","DOIUrl":null,"url":null,"abstract":"<p><strong>Hypothesis: </strong>Lymph node metastases decrease survival in patients with pancreatic neuroendocrine tumors (pNETs).</p><p><strong>Design: </strong>Prospective database searches.</p><p><strong>Setting: </strong>National Institutes of Health (NIH) and Stanford University Hospital (SUH).</p><p><strong>Patients: </strong>A total of 326 patients underwent surgical exploration for pNETs at the NIH (n = 216) and SUH (n = 110).</p><p><strong>Main outcome measures: </strong>Overall survival, disease-related survival, and time to development of liver metastases.</p><p><strong>Results: </strong>Forty patients (12.3%) underwent enucleation and 305 (93.6%) underwent resection. Of the patients who underwent resection, 117 (35.9%) had partial pancreatectomy and 30 (9.2%) had a Whipple procedure. Forty-one patients also had liver resections, 21 had wedge resections, and 20 had lobectomies. Mean follow-up was 8.1 years (range, 0.3-28.6 years). The 10-year overall survival for patients with no metastases or lymph node metastases only was similar at 80%. As expected, patients with liver metastases had a significantly decreased 10-year survival of 30% (P < .001). The time to development of liver metastases was significantly reduced for patients with lymph node metastases alone compared with those with none (P < .001). For the NIH cohort with longer follow-up, disease-related survival was significantly different for those patients with no metastases, lymph node metastases alone, and liver metastases (P < .001). Extent of lymph node involvement in this subgroup showed that disease-related survival decreased as a function of the number of lymph nodes involved (P = .004).</p><p><strong>Conclusions: </strong>As expected, liver metastases decrease survival of patients with pNETs. Patients with lymph node metastases alone have a shorter time to the development of liver metastases that is dependent on the number of lymph nodes involved. With sufficient long-term follow-up, lymph node metastases decrease disease-related survival. Careful evaluation of number and extent of lymph node involvement is warranted in all surgical procedures for pNETs.</p>","PeriodicalId":8298,"journal":{"name":"Archives of Surgery","volume":"147 9","pages":"820-7"},"PeriodicalIF":0.0000,"publicationDate":"2012-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448121/pdf/nihms372428.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1001/archsurg.2012.1261","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Hypothesis: Lymph node metastases decrease survival in patients with pancreatic neuroendocrine tumors (pNETs).
Design: Prospective database searches.
Setting: National Institutes of Health (NIH) and Stanford University Hospital (SUH).
Patients: A total of 326 patients underwent surgical exploration for pNETs at the NIH (n = 216) and SUH (n = 110).
Main outcome measures: Overall survival, disease-related survival, and time to development of liver metastases.
Results: Forty patients (12.3%) underwent enucleation and 305 (93.6%) underwent resection. Of the patients who underwent resection, 117 (35.9%) had partial pancreatectomy and 30 (9.2%) had a Whipple procedure. Forty-one patients also had liver resections, 21 had wedge resections, and 20 had lobectomies. Mean follow-up was 8.1 years (range, 0.3-28.6 years). The 10-year overall survival for patients with no metastases or lymph node metastases only was similar at 80%. As expected, patients with liver metastases had a significantly decreased 10-year survival of 30% (P < .001). The time to development of liver metastases was significantly reduced for patients with lymph node metastases alone compared with those with none (P < .001). For the NIH cohort with longer follow-up, disease-related survival was significantly different for those patients with no metastases, lymph node metastases alone, and liver metastases (P < .001). Extent of lymph node involvement in this subgroup showed that disease-related survival decreased as a function of the number of lymph nodes involved (P = .004).
Conclusions: As expected, liver metastases decrease survival of patients with pNETs. Patients with lymph node metastases alone have a shorter time to the development of liver metastases that is dependent on the number of lymph nodes involved. With sufficient long-term follow-up, lymph node metastases decrease disease-related survival. Careful evaluation of number and extent of lymph node involvement is warranted in all surgical procedures for pNETs.